Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,492JPY
21 Jul 2017
Change (% chg)

¥-15 (-0.60%)
Prev Close
¥2,508
Open
¥2,490
Day's High
¥2,502
Day's Low
¥2,481
Volume
1,185,900
Avg. Vol
1,827,371
52-wk High
¥2,670
52-wk Low
¥2,192

Latest Key Developments (Source: Significant Developments)

EU Medicines Agency recommends approval of Novartis' leukaemia drug
Friday, 21 Jul 2017 07:37am EDT 

July 21 (Reuters) - EU Medicines Agency: :EU Medicines Agency recommendations For July 2017.EU Medicines Agency recommends approval of Pfizer Inc and Merck KGAA Avelumab drug for cell carcinoma‍​.EU Medicines Agency recommends approval of Sanofi and Regeneron Dupixent drug for severe eczema.EU Medicines Agency recommends approval Of Roche Tecentriq drug for drug for bladder and lung cancer‍​.EU Medicines Agency recommends approval Of Advanced Accelerator Applications Lutathera drug for gastroenteropancreatic neuroendocrine tumours.EU Medicines Agency recommends against approval of Nektar Therapeutics and Daiichi Sankyo Onzeald drug for breast cancer.EU Medicines Agency recommends approval of Novartis Rydapt drug for leukaemia.  Full Article

C&Kim buys 10.6 pct stake in HansolNexG
Monday, 3 Jul 2017 11:04pm EDT 

July 4 (Reuters) - HansolNexG Co Ltd <081970.KQ> ::* Says C&Kim Co Ltd has acquired 613,100 shares of the co, and is holding 10.6 percent stake in the co, from 0 percent stake .  Full Article

Daiichi Sankyo announces top-line results from phase 3 global clinical development program evaluating mirogabalin in pain syndromes
Friday, 30 Jun 2017 07:00am EDT 

June 30 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>:Daiichi Sankyo announces top-line results from phase 3 global clinical development program evaluating mirogabalin in pain syndromes.Daiichi Sankyo Co Ltd - Preliminary and ongoing analyses indicated no unexpected safety concerns in neucourse or alday clinical trials.Daiichi Sankyo Co Ltd - In phase 3 alday clinical trials, mirogabalin did not meet primary efficacy endpoint.Says ‍in neucourse, mirogabalin met primary efficacy endpoint​.  Full Article

Daiichi Sankyo to invest 22 bln yen in U.S. for Luitpold Pharmaceuticals - Nikkei
Wednesday, 24 May 2017 04:30pm EDT 

May 25 (Reuters) - Nikkei::Daiichi Sankyo to invest 22 billion yen in U.S. for Luitpold Pharmaceuticals; targets about 70 pct rise in Luitpold's sales to 150 billion yen in fiscal 2020 versus 2015 - Nikkei.  Full Article

Daiichi Sankyo makes 15 bln yen investment
Thursday, 27 Apr 2017 08:00am EDT 

April 27 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::Daiichi Sankyo - making initial 15 billion yen investment to optimize and enhance manufacturing capabilities to support growing antibody drug conjugate pipeline.  Full Article

GSK seeks Japanese approval for shingles vaccine
Tuesday, 18 Apr 2017 04:16am EDT 

April 18 (Reuters) - GlaxoSmithKline Plc ::Gsk vaccine submission for shingles in japan.JV between GSK, Daiichi Sankyo submitted new drug application in Japan seeking approval for candidate shingles vaccine, shingrix.  Full Article

HTG Molecular says entered into master services agreement with Daiichi Sankyo Company
Monday, 17 Apr 2017 07:30am EDT 

April 17 (Reuters) - Htg Molecular Diagnostics Inc :Htg molecular diagnostics - entered into master services agreement with daiichi sankyo company, ltd for work to be performed in htg's veri/o laboratory.Htg molecular diagnostics - initial project includes development of custom assay for detection of nearly 3,000 mrna targets using htg edgeseq technology.  Full Article

Sosei Group unit signs alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED.
Monday, 13 Mar 2017 03:16am EDT 

Sosei Group Corp <4565.T>:Says its subsidiary Heptares signed an alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED. on March 13.  Full Article

Amring Pharmaceuticals says acquired six ANDAs from Luitpold Pharmaceuticals, Alphaforce L.L.P.
Thursday, 9 Mar 2017 11:59am EST 

Amring Pharmaceuticals Inc : Amring pharmaceuticals inc - acquired six andas from luitpold pharmaceuticals inc and alphaforce l.l.p. .Amring pharmaceuticals inc - acquired andas include niche otic and ophthalmic pharmaceuticals.  Full Article

EMA recommends approval of Daiichi Sankyo's anticoagulant
Friday, 24 Feb 2017 07:00am EST 

EU Medicines Agency: EU medicines Agency recommendations for February 2017 . EU Medicines Agency recommends approval Of Daiichi Sankyo's anticoagulant Edoxaban . EU Medicines Agency says adopted positive opinion recommending changes to the terms of the marketing authorisation for the medicinal product Darzalex . EU Medicines Agency recommends approval of Hospira UK Limited's Pemetrexed for treatment of non-small cell lung cancer Source (http://bit.ly/2lCHPks) Further company coverage: [4568.T] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Photo

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.